What Aexon Labs does

Aexon Labs, Inc. is a pre-revenue, privately held pharmaceutical R&D company domiciled in Delaware (headquartered at 16192 Coastal Hwy, Lewes) that is developing a portfolio of dual non-sulfonamide orexin receptor agonists for neurodegenerative and neurological disorders. The company's core technology is a first-in-class non-sulfonamide platform targeting both OX1R and OX2R receptors with an integrated cathepsin H (CTSH) inhibition mechanism, designed to address neuroinflammation underlying narcolepsy, synucleinopathies (Parkinson's disease, Dementia with Lewy Body, Multiple System Atrophy), and Alzheimer's disease. The platform comprises named lead compounds AEX-23, AEX-19, and AEX-24, each characterized by OX1R agonist activity, neurite outgrowth effects, and Cathepsin D modulation, with AEX-24 specifically positioned for alpha-synuclein degradation enhancement. Compounds are designed as Lipinski-rule-of-five-compliant aromatic heterocycles with solubility characterized across pH 0 to pH 13. The company has no current commercial revenue, no disclosed funding rounds, and no headcount data; its stated go-to-market pathway is licensing agreements or partnerships with established pharmaceutical companies for global commercialization contingent on successful clinical development. Co-founders Eric Konofal (MD, PhD; 88+ patents, 76+ peer-reviewed publications, also co-founder of NASDAQ-listed NLS Pharmaceutics) and Anh-Tuan Lormier (PhD Chemistry; co-founder/President of CayLab) lead the scientific program, and the company has presented at the ASCP Annual Meetings in 2024 and 2025.

Name

Aexon Labs

Legal name

Aexon Labs. Inc

Website

https://aexonlabs.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Aexon Labs is a pre-revenue Delaware-based biotech developing non-sulfonamide dual orexin receptor agonists (AEX-23, AEX-19, AEX-24) targeting neuroinflammation for narcolepsy, Parkinson's, and Alzheimer's disease, with planned commercialization via pharmaceutical licensing or partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Orexin receptor agonists
• Neurodegenerative disease therapeutics
• CNS drug discovery
• Narcolepsy therapeutics
• Medicinal chemistry research

Headquarters

HQ city

Lewes

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

Aexon Labs is a biotechnology R&D company developing a portfolio of novel non-sulfonamide dual orexin receptor agonist compounds (AEX-23, AEX-19, AEX-24) that target both OX1R and OX2R receptors with integrated Cathepsin H (CTSH) inhibitory properties for neurodegenerative and CNS disorders including narcolepsy type 1, Parkinson's disease, and Alzheimer's disease. The compounds are designed as innovative aromatic heterocyclic molecules following Lipinski's rule of five, protected by international PCT patent application WO2024115797 (filed 30/12/2022). The company is pre-revenue and intends to commercialize approved therapeutics through licensing or partnership with established pharmaceutical companies.

Product overview

Aexon Labs is a pharmaceutical/biotechnology company developing a portfolio of innovative therapeutic compounds for neurodegenerative disorders. The core offering is the AEX Compounds platform—a first non-sulfonamide dual orexin receptor agonist technology targeting both OX1R and OX2R receptors, with specific named compounds including AEX-23, AEX-19, and AEX-24. These compounds also incorporate Cathepsin H (CTSH) inhibitory properties and are being developed for conditions including narcolepsy with cataplexy, synucleinopathies (Parkinson's disease), and Alzheimer's disease. The company has an international PCT patent portfolio (WO2024115797) protecting their novel aromatic heterocyclic compounds designed with favorable physicochemical properties following Lipinski's rule of five.

Differentiator

Problem solved

Functional benefit

Products and services

• AEX Compounds Platform (Dual Non-Sulfonamide Orexin Receptor Agonists) A proprietary drug-discovery platform of innovative aromatic heterocyclic dual orexin receptor agonists targeting OX1R and OX2R with integrated Cathepsin H (CTSH) inhibitory properties, designed with favorable Lipinski-rule-of-five physicochemical and biopharmaceutical properties. Intended for development into therapeutics for neurodegenerative disorders including narcolepsy, Parkinson's disease, and Alzheimer's disease, with eventual commercialization via licensing or partnership with large pharmaceutical companies.
• AEX-23 Compound A specific AEX lead compound demonstrating significant OX1R agonist activity combined with positive effects on neurite outgrowth, suggesting modulation of neuronal health through pathways influencing alpha-synuclein dynamics and positioning it as a potential therapeutic candidate for Parkinson's disease.
• AEX-19 Compound A specific AEX lead compound showing effects at low concentrations on neurite growth, coupled with significant OX1R agonist activity and a moderate increase in Cathepsin D (CTSD) activity, suggesting potential neuroprotective benefits in Parkinson's disease.
• AEX-24 Compound A specific AEX lead compound demonstrating significant increase in Cathepsin D (CTSD) activity and OX1R agonist activity, suggesting potential to enhance alpha-synuclein degradation with promising therapeutic impact on Parkinson's disease.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Anavex Life Sciences: Anavex develops sigma-1 receptor agonists for Alzheimer's, Rett syndrome, and Parkinson's — directly mirroring Aexon's CNS mechanism approach (sigma-1 + neuroinflammation) and providing a comparable small-cap neurodegenerative biotech peer.
• Axsome Therapeutics: Axsome is a CNS-focused commercial-stage biotech with approved therapies (e.g., Auvelity, Sunosi-related assets) addressing high-unmet-need neurological indications, providing a comparable commercial-stage CNS biotech template for Aexon's future trajectory.
• Sage Therapeutics: Sage develops CNS therapies for depression and neurology, including Zurzuvae. It shares Aexon's profile of targeting high-unmet-need CNS indications with novel mechanisms and is a relevant comp for biotech-stage CNS valuations and partnership dynamics.
• Cassava Sciences: Cassava (simufilam) is a clinical-stage biotech focused on Alzheimer's disease. As a single-asset CNS neurodegenerative company, it offers a comparable public-market template for Aexon's AD program trajectory.

Direct peers

• Jazz Pharmaceuticals: Jazz markets Xywav (oxybate) and Sunosi (solriamfetol) for narcolepsy with cataplexy and excessive daytime sleepiness, directly competing for the same NT1 patient population that Aexon's dual orexin agonist platform targets.
• Denali Therapeutics: Denali is a clinical-stage biotech developing therapies for neurodegeneration (PD, AD, ALS) with novel small molecules targeting lysosomal function and neuroinflammation — directly aligned with Aexon's cathepsin/neuroinflammation thesis.
• NLS Pharmaceutics: NLS Pharmaceutics (NASDAQ: NLSP) is co-founded by Aexon's co-founder Eric Konofal and focuses on rare CNS disorders, including orexin-related therapies. It is the closest direct peer in terms of scientific lineage, therapeutic focus, and capital-market profile.
• Avadel Pharmaceuticals: Avadel's Lumryz is an extended-release oxybate approved for narcolepsy with cataplexy. It competes head-to-head with Jazz's Xywav in the same EDS/cataplexy market Aexon is targeting.

Broad incumbents

• Takeda Pharmaceutical: Takeda developed TAK-994, the leading dual orexin receptor agonist for narcolepsy that was discontinued due to hepatotoxicity. As the originator of the orexin therapeutic class, Takeda is the most direct reference point for Aexon's non-sulfonamide re-entry strategy.
• Biogen: Biogen is a major player in Alzheimer's (Aduhelm, Leqembi via partnership) and Parkinson's, with established CNS development infrastructure that could serve as both a competitor and a potential acquirer/partner for Aexon's neurodegenerative pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AexonLabs
• Facebookfacebook.com/aibbrokers
• LinkedInlinkedin.com/company/aexon-labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aexon Labs